GSK Bolsters Cardiovascular Portfolio With Acquisition Of Reliant
Executive Summary
GlaxoSmithKline's acquisition of Reliant for $1.65 billion will give the U.K. drug maker access to a growing cardiovascular drug in the U.S., Lovaza. The drug will complement GSK's existing CV portfolio, including the hypertension drug Coreg CR
You may also be interested in...
Generic Coreg To Launch Immediately Following FDA Approval
The first generic versions of GlaxoSmithKline's blockbuster heart failure medication Coreg (carvedilol) will launch immediately following FDA's Sept. 5 approval of several ANDAs for the beta blocker
Reliant Will Add Antara, Omacor To Cardiovascular Product Line In 2005
Reliant will launch two recently-approved cardiovascular products, Antara and Omacor, in 2005
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.